These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 29742934)

  • 1. Drug Information Association Pharmacovigilance and Risk Management Strategies 2017: Overview of the Generic Drug Program and Surveillance.
    Chazin HD; Peters JR; Catterson DM; Osterhout JL; Forsyth LM; Lee JE; Kim EK; Feibus KB
    Ther Innov Regul Sci; 2019 Mar; 53(2):249-253. PubMed ID: 29742934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interchangeability, Safety and Efficacy of Modified-Release Drug Formulations in the USA: The Case of Opioid and Other Nervous System Drugs.
    Seoane-Vazquez E; Rodriguez-Monguio R; Hansen R
    Clin Drug Investig; 2016 Apr; 36(4):281-92. PubMed ID: 26818406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.
    Ting TY; Jiang W; Lionberger R; Wong J; Jones JW; Kane MA; Krumholz A; Temple R; Polli JE
    Epilepsia; 2015 Sep; 56(9):1415-24. PubMed ID: 26201987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Product-Specific Regulatory Pathways to Approve Generic Drugs: The Need for Follow-up Studies to Ensure Safety and Effectiveness.
    Kesselheim AS; Gagne JJ
    Drug Saf; 2015 Oct; 38(10):849-53. PubMed ID: 26105011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physicians' Trust in the FDA's Use of Product-Specific Pathways for Generic Drug Approval.
    Kesselheim AS; Eddings W; Raj T; Campbell EG; Franklin JM; Ross KM; Fulchino LA; Avorn J; Gagne JJ
    PLoS One; 2016; 11(10):e0163339. PubMed ID: 27768700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs.
    Borgheini G
    Clin Ther; 2003 Jun; 25(6):1578-92. PubMed ID: 12860486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes.
    Kesselheim AS; Polinski JM; Fulchino LA; Isaman DL; Gagne JJ
    Drugs; 2015 Apr; 75(6):633-50. PubMed ID: 25822610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Confidence in generic drug substitution.
    Lionberger R; Jiang W; Huang SM; Geba G
    Clin Pharmacol Ther; 2013 Oct; 94(4):438-40. PubMed ID: 24048239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is Bioequivalence a Sufficient Measure of Equivalence?
    Holman A
    J Leg Med; 2019; 39(3):247-261. PubMed ID: 31626574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addressing the Regulatory and Scientific Challenges with Generic Orally Inhaled Drug Products.
    Newman B; Witzmann K
    Pharmaceut Med; 2020 Apr; 34(2):93-102. PubMed ID: 32112304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switch-backs associated with generic drugs approved using product-specific determinations of therapeutic equivalence.
    Gagne JJ; Polinski JM; Jiang W; Dutcher SK; Xie J; Lii J; Fulchino LA; Kesselheim AS
    Pharmacoepidemiol Drug Saf; 2016 Aug; 25(8):944-52. PubMed ID: 27102378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk-Based Bioequivalence Recommendations for Antiepileptic Drugs.
    Li Z; Fang L; Jiang W; Kim MJ; Zhao L
    Curr Neurol Neurosci Rep; 2017 Sep; 17(11):82. PubMed ID: 28929357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Product selection, bioequivalence, and therapeutic equivalence: the generic drug market.
    Halperin JA
    Drug Inf J; 1983; 17(2):73-6. PubMed ID: 10263719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical equivalence by design for generic drugs: modified-release products.
    Raw AS; Lionberger R; Yu LX
    Pharm Res; 2011 Jul; 28(7):1445-53. PubMed ID: 21387150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From antiretroviral originator to generic drugs: bioequivalence and pharmacovigilance.
    Bagheri H; Garraffo R; Dellamonica P
    Med Mal Infect; 2014 Oct; 44(10):464-9. PubMed ID: 25234382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies That Delay Market Entry of Generic Drugs.
    Vokinger KN; Kesselheim AS; Avorn J; Sarpatwari A
    JAMA Intern Med; 2017 Nov; 177(11):1665-1669. PubMed ID: 28975217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of reporting of bioequivalence trials comparing generic to brand name drugs: a methodological systematic review.
    van der Meersch A; Dechartres A; Ravaud P
    PLoS One; 2011; 6(8):e23611. PubMed ID: 21858184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical attributes of transdermal drug delivery system (TDDS)--a generic product development review.
    Ruby PK; Pathak SM; Aggarwal D
    Drug Dev Ind Pharm; 2014 Nov; 40(11):1421-8. PubMed ID: 24467407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis for bioequivalence review.
    Chow SC; Liu J
    J Biopharm Stat; 1997 Mar; 7(1):97-111. PubMed ID: 9056591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.